| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.
|
Nat Med
|
2005
|
5.09
|
|
2
|
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
|
Lancet
|
2011
|
4.15
|
|
3
|
Structural basis of West Nile virus neutralization by a therapeutic antibody.
|
Nature
|
2005
|
3.51
|
|
4
|
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.
|
PLoS Pathog
|
2010
|
3.16
|
|
5
|
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
|
J Mol Biol
|
2007
|
2.45
|
|
6
|
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.
|
J Virol
|
2010
|
2.14
|
|
7
|
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.
|
PLoS Pathog
|
2010
|
2.03
|
|
8
|
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
|
Blood
|
2011
|
1.95
|
|
9
|
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.
|
J Infect Dis
|
2006
|
1.84
|
|
10
|
Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
|
J Virol
|
2010
|
1.58
|
|
11
|
Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants.
|
J Exp Med
|
2011
|
1.53
|
|
12
|
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
|
Cancer Res
|
2007
|
1.48
|
|
13
|
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.
|
PLoS Pathog
|
2013
|
1.47
|
|
14
|
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.
|
Cell Host Microbe
|
2007
|
1.37
|
|
15
|
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope.
|
PLoS Pathog
|
2012
|
1.31
|
|
16
|
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.
|
Antimicrob Agents Chemother
|
2007
|
1.30
|
|
17
|
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.
|
Cell Host Microbe
|
2009
|
1.27
|
|
18
|
Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.
|
J Virol
|
2011
|
1.24
|
|
19
|
Capturing a flavivirus pre-fusion intermediate.
|
PLoS Pathog
|
2009
|
1.24
|
|
20
|
Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice.
|
Proc Natl Acad Sci U S A
|
2010
|
1.23
|
|
21
|
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
|
J Virol
|
2013
|
1.22
|
|
22
|
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].
|
PLoS Pathog
|
2013
|
1.20
|
|
23
|
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
|
Diabetes
|
2013
|
1.19
|
|
24
|
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
|
J Clin Invest
|
2015
|
1.13
|
|
25
|
Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
|
Immunology
|
2007
|
1.10
|
|
26
|
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
|
J Infect Dis
|
2004
|
1.10
|
|
27
|
IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.
|
Immunol Lett
|
2009
|
1.08
|
|
28
|
CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.
|
Blood
|
2006
|
1.07
|
|
29
|
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
|
Clin Cancer Res
|
2012
|
1.06
|
|
30
|
West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons.
|
J Neurovirol
|
2008
|
1.01
|
|
31
|
Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.
|
Virology
|
2009
|
0.97
|
|
32
|
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
|
Breast Cancer Res
|
2011
|
0.96
|
|
33
|
Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus.
|
Antimicrob Agents Chemother
|
2010
|
0.92
|
|
34
|
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
|
Arthritis Rheum
|
2010
|
0.92
|
|
35
|
Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.
|
J Virol
|
2013
|
0.90
|
|
36
|
Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
|
Adv Enzyme Regul
|
2007
|
0.87
|
|
37
|
Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice.
|
Crit Care Med
|
2011
|
0.80
|
|
38
|
Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.
|
Toxicol Sci
|
2011
|
0.76
|